SCENESSE®: Commercialization of a First-In-Class NCE

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

please check before submitting

Mobile number:

What is your role?

Privacy statement »

Manage your email preferences »

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

Nicoletta Muner of Clinuvel Pharmaceuticals Ltd. joined us for World Orphan Drug Congress USA 2015 to present about ' SCENESSE® :Commercialization of a First-In-Class NCE'

Download her presentation now to understand more about:

Scenesse Clincial Program
Erythropoietic Protoporphyria (EPP)
EPP Clinical Development and Expanded Access
EMA Evaluation (Centralised Procedur)

...and much more!

Get your copy here!

To find out more about SCENESSE® , attend World Orphan Drug Congress USA 2016 April 20-22 in Washington, DC.

SCENESSE®: Commercialization of a First-In-Class NCE

information we require

please check before submitting